COVID-19 vaccine made in Chengdu approved for clinical trials in Mexico

As the EPC general contractor of WestVac Biopharma COVID-19 Vaccine Project, Tofflon provides turnkey services, including process equipment, engineering design, engineering construction, commissioning, GMP validation and accompanied service in PQ.

Author：

According to WestVac Biopharma, Mexican Medicine Agency has issued a permit for phase I/II clinical studies on the recombinant variant novel COVID-19 vaccine (Sf9 cells) jointly developed by WestVac Biopharma and West China Hospital of Sichuan University. This is a second-generation recombinant protein vaccine for novel COVID-19 vaccine such as Omicron. At present, WestVac Biopharma has submitted application for phase I/II clinical trials of recombinant variant novel COVID-19 vaccine (Sf9 cells) in many places including China and Japan. This Mexican authorization will further accelerate the development of the recombinant variant novel COVID-19 vaccine (Sf9 cells). As the EPC general contractor of WestVac Biopharma COVID-19 Vaccine Project, Tofflon provides turnkey services, including process equipment, engineering design, engineering construction, commissioning, GMP validation and accompanied service in PQ.